Synthesis and in vitro evaluation of a novel radioligand for αvβ3 integrin receptor imaging: [¹⁸F]FPPA-c(RGDfK)
Monaco, AlessandraCyclotron Unit, University Hospital of Geneva, Switzerland - School of Pharmaceutical Sciences, University of Geneva and University of Lausanne, Switzerland
Zoete, VincentSwiss Institute of Bioinformatics, University of Lausanne, Switzerland
Alghisi, Gian CarloUniversity of Lausanne, Division of Experimental Oncology, Multidisciplinary Oncology Center, Switzerland
Rüegg, CurzioUniversity of Lausanne, Division of Experimental Oncology, Multidisciplinary Oncology Center, Switzerland - University of Fribourg, Faculty of Science, Department of Medicine, Switzerland
Michelin, OlivierSwiss Institute of Bioinformatics, University of Lausanne, Switzerland
Prior, JohnCHUV, Department of Nuclear Medicine, Lausanne, Switzerland
Scapozza, LeonardoSchool of Pharmaceutical Sciences, University of Geneva and University of Lausanne, Switzerland
Seimbille, YannCyclotron Unit, University Hospital of Geneva, Switzerland - School of Pharmaceutical Sciences, University of Geneva and University of Lausanne, Switzerland
English
The development of RGD-based antagonist of αvβ3 integrin receptor has enhanced the interest in PET probes to image this receptor for the early detection of cancer, to monitor the disease progression and the response to therapy. In this work, a novel prosthetic group (N-(4-fluorophenyl)pent-4-ynamide or FPPA) for the 18F-labeling of an αvβ3 selective RGD-peptide was successfully prepared. [18F]FPPA was obtained in three steps with a radiochemical yield of 44% (decay corrected). Conjugation to c(RGDfK(N3)) by the Cu(II) catalyzed Huisgen azido alkyne cycloaddition provided the [18F]FPPA-c(RGDfK) with a radiochemical yield of 29% (decay corrected), in an overall synthesis time of 140 min.